These findings indicate that, with the development of precision medicine and personalized oncology therapy, it is likely that the assessment of breast pCR can be achieved preoperatively, especially in triple-negative and HER2-positive breast cancers, where pCR is more easily achieved. This evidence concerns the gene ERBB2 and breast cancer.